Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones

References

• FUJITA T, SUGIYAMA Y, TAKETOMI S, SHODA T,KAWAMATSU Y, IWATSUKA H, SUZUOKI Z: Reduction of Insulin resistance in obese and/or diabetic animals by 3[-4-(1 methylcyclohexylmethoxy) benzyn-thiazolid-ine-2,4 dione (ADD-3870, U-63287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804–810,
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, YOSHIOKA S, YOSHIOKA T, USHIYAMA I,HORIKOSHI H: Characterization of a new and antidia-betic agent, CS-045. Studies in ICK and ob/ob mice and Zucker fatty rats. Diabetes (1988) 37:1849–1888.
   Google Scholar
• LEE MK, MILES PDG, KHOURSHEED M, GAO KM, MOSSAAR, OLEFSKY JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes (1994) 43:1435–1439.
   PubMed Web of Science ®Google Scholar
• KHOURSHEED M, MILES PDG, GAO KM, LEE MK, MOSSAAR, OLEFSKY JM: Metabolic effects of troglitazone on fat Induced insulin resistance in the rat Metabolism (1995). In press.
   Google Scholar
• TOMINAGA M, IGARASHI M, DAIMON M, EGUCHI H,MATSUMOTO M, SEKLKAWA A, YAMATOMI K, SASAKI H: Thiazondinediones (AD-4533 and CS-045) improve he-patic insulin resistance in streptozotocin-induced dia-betic rats. Endocrine J. (1993) 40:343–349.
   PubMed Web of Science ®Google Scholar
• STEVENSON RW, MCPHERSON RK, GENEREUX BE, DAN-BURY BH, KREUTTER DK: Antidiabetic agent Englitazone enhances insulin action in nondiabetic rats without produdng hypoglycemia. Metabolism (1991) 40:1268–1274.
   PubMed Web of Science ®Google Scholar
• BOWEN L, STEVEN PP, STEVENSON R, SHULMAN CI: Theeffect of CP-68772, a thiazolidine derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism (1991) 40:1025–1030.
   PubMed Web of Science ®Google Scholar
• OAKES ND, KENNEDY CJ, JENKINS AB, LAYBULF DR,CHISHOLM DJ, KRAEGEN EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves Insulin action and glucoregulation in the rat. Diabetes (1994) 43:1203–1210.
   PubMed Web of Science ®Google Scholar
• HOFMANN C, LORENZ K, COLCA JR: Glucose transport defldency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology (1991) 129:1915–1925.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA Y, SHIMURA Y, IKEDA H: Effects of pioglita-zone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim Forschung (1990) 40:436–440.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, OKUNO A, YOSHIOKA S, HORIKOSHI H: Suppression of hepatic gluconeogenesis in chronic troglitazone (CS-045)-treated diabetic KK and C57BL/KSJ4b/db mice. Metabolism (1995). In press.
   Google Scholar
• FUJIWARA T, WADE M, FUKUDA K, FUKAMI M, YOSHIOKOS, YOKIOSHO T, HORIKOSHI H: Characterization of CS-045, a new oral antidiabetic agent. IL Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/ICSJ-db/db mice. Metabolism (1991) 40:1213–1218.
   Google Scholar
• REAVEN GM: Role of insulin resistance in human dis-ease. Diabetes (1988) 37:1595–1607.
   PubMed Web of Science ®Google Scholar
• YOSHIOKO J, NISHIYAMA H, SHIROKI T, IKEDA K, KOIKEH, WADE M, FUJIWARA T, HORIKOSHI H: Antihyperten-sive effects of CS-045 treatment in obese Zucker rats. Metabolism (1993) 42:75–80.
   PubMedGoogle Scholar
• ZHANG HY, REDDY SR, KOTCHAN TA: Antihypertensiveeffect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension (1994) 24:106–110.
   PubMed Web of Science ®Google Scholar
• KEMNITZ JW, ELSON DF, ROECKER EB, BAUM ST, BERGMAN RN, MEGLESSON MD: Pioglitazone increases Insulin sensitivity, reduces blood glucose, insulin and lipid levels, and lowers blood pressure in obese, insu-lin-resistant rhesus monkeys. Diabetes (1994) 33:203–211.
   Google Scholar
• SUGIYAMA Y, TEKETOMI S, SHIMUOA V, IKEDA H, FUJTTAT: Effects of pioglitazone on glucose and lipid metabo-lism in Wistar fatty rats. Arzneim Forschung (1994) 40:263–267.
   Google Scholar
• KRAEGEN E, JAMES D, JENKINS AB, CHISHOLD OJ, STAR-UN LH: A potent in vivo effect of ciglitazone on muscle Insulin resistance induced by high fat feeding of rats. Metabolism (1989) 38:1089–1093.
   PubMed Web of Science ®Google Scholar
• CASTLE CK, COLCA JR, MELCHIOR GW: Lipoprotein pro-file characterization of the ICKA mouse, a rodent model of Type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler. Thromb. (1992) 13:307–309.
   Google Scholar
• Saltiel AR: The paradoxical regulation of protein phos-phorylation by insulin. EASES J. (1994) 8:1034–1040.
   Google Scholar
• KLETZIEN RF, CLARK SD, ULRICH RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. (1992) 41:393–398.
   PubMed Web of Science ®Google Scholar
• OHSUMI J, SAKAK1BARA S, YAMAGUCHI J, MIYADAI K, YOSHIOKO S, FUJIWARA T, HORIKOSHI H, SERIZAWA N: TroglitarAme prevents the inhibitory effects of inflam-matory cytokines on insulin-induced adipocyte differ-entiation in 3T3-L1 cells. Endocrinology (1994) 135:2279–2282.
   PubMed Web of Science ®Google Scholar
• SANDOUK T, REDA D, HOFMANN C: Antidiabetic agentpioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am. J. Physiol. (1993) 264:C1600–C1608.
   PubMed Web of Science ®Google Scholar
• TAFURI S: Troglitazone stimulates glucose uptake in 3T3-L1 adipocytes by enhancing expression of the Glutl and Glut4 glucose transporters. Diabetes (1994) 43:761A.
   Google Scholar
• KREUTTER DK, ANDREWS KM, GIBBS EM, HUTSON NJ, STEVENSON RW: Insulin-like activity of new antidiabetic agent CP68722 in 3T3-L1 adipocytes. Diabetes (1990) 39:1414–1419.
   PubMed Web of Science ®Google Scholar
• SANDOUK T, REDA D, HOFMANN C: The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messen-ger ribonucleic acid transcript stability. Endocrinology (1993) 133:352–359.
   PubMed Web of Science ®Google Scholar
• EL-KEBBI IM, ROSER S, POLLET RJ: Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism (1994) 43:953–958.
   PubMed Web of Science ®Google Scholar
• AMRI E-Z, BONINO F, AILHAUD G, ABUMARAD NA, GRI-MALDI PA: Cloning of a protein that mediates transcrip-tional effects of fatty acids in preadipocytes. J. Biol. Chem. (1995). In press.
   Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISON WO, WILLSON TM, KLIEWER SA: An antidiabetic thb-zolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPARy). J. Biol. Chem. (1995) 270(22):12953–12956.
   PubMed Web of Science ®Google Scholar
• CIRALDI TP, GILMORE A, OLEFSKY JM, GOLDBERG M,HEIDENREICH KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism (1990) 39:1056–1062.
   PubMedGoogle Scholar
• LI WW, LEFF T: Regulation of hepatic glucokinase gene transcription by troglitawne. Submitted for publication.
   Google Scholar
• CARO JF, SINHA MK, RAJU JM, ITOOP O, PARIES WJ, FLICKINGER EL, MEELHEIM D, POHM GL: Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J. Clin. Invest. (1987) 79:1330–1337.
   PubMed Web of Science ®Google Scholar
• MULLER HK, KELLERER M, ERMEL B, MUHLHOFER A, OBERMALER-KUSSER B, VOGT B, HARING HU: Prevention by protein kinase C inhibitors of glucose-induced insu-lin receptor tyrosine kinase resistance in rat fat cells. Diabetes (1991) 40:1440–1448.
   PubMed Web of Science ®Google Scholar
• BALER S, KIEHN R, HARING HU: Effect of CS-045 on the activity of insulin receptor kinase in the skeletal muscle of insulin resistant Zucker rats. Diabetes Stoffweschel (1993) 2:56–61.
   Google Scholar
• KEJIFRER M, KRODER G, TLPPMER S, BERTI L, KIEHN R, MOSTHAF L, HARING HU: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat 1 fibroblasts. Diabetes (1994) 43:447–453.
   PubMed Web of Science ®Google Scholar
• HOFMANN CA, COLCA JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care (1992) 15:1075–1078.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KUZUYA T, MATSUDA A, AWATA T, KU- MAKURA S, INOOKA G, SHIRAISHI I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NTDDM. Diabetes Care (1991) 14:1083–1086.
   PubMed Web of Science ®Google Scholar
• GHAZZI M, BALAGTAS C, PEREZ J, WHITCOMB R: Treat-ment of NIDDM patients with troglitazone is not asso-ciated with increased cardiac mass or impaired cardiac function. 55th Annual Meeting of the American Diabetes Association (1995):574.
   Google Scholar
• SUTER SL, NOLAN JJ, WALLACE P, GUMBINER B, OLEFSKYJM: Metabolic effects of new oral hypoglycemic agent CS-045 In NIDDM subjects. Diabetes Caw (1992) 15:193–203.
   PubMed Web of Science ®Google Scholar
• VALIQUETT T, BALAGTAS C, WHITCOMB R: Troglitazonedose-response study in patients with NIDDM. 55th An-nual Meeting of the American Diabetes Association (1995):406.
   Google Scholar
• FOOT EA, PATEL J, WILLIAMS ZV, ECKLAND DJA: Im-proved metabolic control by addition of troglitazone to glibendamide therapy in non-insulin-dependent dia-betes. 31st EASD. Stockholm, Sweden (1995):A44.
   Google Scholar
• HARRIS MI: Impaired glucose tolerance in the US popu-lation. Diabetes Care (1989) 12:464–474.
   PubMed Web of Science ®Google Scholar
• SAAD MF, KNOWLER WC, PETTIT DJ, NELSON RG, MOTT DM, BENNETT PH: Natural history of IGT in Pima Indi-ans. New Engl.'. Med. (1988) 319:1500–1506.
   PubMed Web of Science ®Google Scholar
• WINGARD DL, SCHEIDT-NAVE C, BARRETT-CONNOR EL, MCPHILLIPS JB: Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. Diabetes Care (1993) 12:1022–1025.
   Google Scholar
• NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY JM: Improvement in glucose tolerance and insulin re-sistance in obese subjects treated with troglitazone. New Engl. J. Med. (1994) 331:1188–1193.
   PubMed Web of Science ®Google Scholar
• ANTONUCCI T, NORRIS R, MCCLAIN R, WHITCOMB R: An Investigator-blinded, randomized, multicenter, pla-cebo-controlled trial of the effect of troglitazone (CI-991) on impaired glucose tolerance (IGT) and insulin resistance. 54th Annual Meeting of the American Diabetes Association (1994):253.38.
   Google Scholar